Abstract
The respiratory syncytial virus (RSV) vaccine was officially offered to pregnant individuals in 2023-2024, with the purpose of providing immunity to infants and young children. We performed a retrospective review to determine the rate of offering the RSV vaccine and acceptance of the vaccine among patients between 32 0/7 and 36 6/7 weeks of gestation. A prospective survey was administered to examine barriers to RSV vaccination. We identified 206 patients, including 111 (53.8%) who were offered the vaccine and 95 (46.1%) who were not offered the vaccine. Of those who were offered the vaccine, 62 (55.9%) accepted and 49 (44.1%) declined. Individuals who declined had significantly higher rates of declining other vaccines in pregnancy (P<.001). More than half of those who declined the RSV vaccine reported both accepting the RSV antibody for their newborn and plans of accepting the vaccine in subsequent pregnancies.